Literature DB >> 21138983

Severe hemorrhagic corpus luteum complicating anticoagulation in antiphospholipid syndrome.

L Y S Yamakami1, D B de Araujo, C A Silva, E C Baracat, J F de Carvalho.   

Abstract

Antiphospholipid syndrome (APS) is a disorder of coagulation that causes thrombosis as well as pregnancy-related complications, occurring due to the autoimmune production of antibodies against phospholipid. Full anticoagulation is the cornerstone therapy in patients with thrombosis history, and this can lead to major bleeding. During a 3-year period, 300 primary and secondary APS patients were followed up at the Rheumatology Division of the authors' University Hospital. Of them, 255 (85%) were women and 180 (60%) were of reproductive age. Three of them (1%) had severe hemorrhagic corpus luteum while receiving long-term anticoagulation treatment and are described in this report. All of them were taking warfarin, had elevated international normalized ratio (>4.0) and required prompt blood transfusion and emergency surgery. Therefore, we strongly recommend that all women with APS under anticoagulation should have ovulation suppressed with either intramuscular depot-medroxyprogesterone acetate or oral desogestrel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21138983     DOI: 10.1177/0961203310383300

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  4 in total

Review 1.  Which Hormones and Contraception for Women with APS? Exogenous Hormone Use in Women with APS.

Authors:  Lisa R Sammaritano
Journal:  Curr Rheumatol Rep       Date:  2021-04-30       Impact factor: 4.592

Review 2.  Hemorrhagic corpus luteum: Clinical management update.

Authors:  Mykhailo V Medvediev; Antonio Malvasi; Sarah Gustapane; Andrea Tinelli
Journal:  Turk J Obstet Gynecol       Date:  2020-12-10

Review 3.  Special Considerations for Women of Reproductive Age on Anticoagulation.

Authors:  Tali Azenkot; Eleanor Bimla Schwarz
Journal:  J Gen Intern Med       Date:  2022-05-31       Impact factor: 6.473

Review 4.  Corpus luteum hemorrhage with acquired hemophilia A: a case report and literature review.

Authors:  Xiaofei Xie; Shaoru Jiang
Journal:  BMC Womens Health       Date:  2022-10-11       Impact factor: 2.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.